UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.15 Billion Position in Danaher Corporation $DHR

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Danaher Corporation (NYSE:DHR) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,011,650 shares of the conglomerate’s stock after selling 23,253 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Danaher were worth $1,147,267,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Elevated Capital Advisors LLC acquired a new position in shares of Danaher during the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Danaher during the fourth quarter worth about $27,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after buying an additional 53 shares during the period. JPL Wealth Management LLC acquired a new position in shares of Danaher during the third quarter worth about $25,000. Finally, WFA of San Diego LLC acquired a new position in shares of Danaher during the second quarter worth about $26,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

DHR opened at $179.95 on Friday. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a market capitalization of $127.37 billion, a PE ratio of 34.81, a PEG ratio of 2.41 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The business’s 50-day simple moving average is $180.93 and its 200 day simple moving average is $204.78.

Danaher (NYSE:DHR) last released its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the company posted $1.88 earnings per share. Danaher’s revenue was up 3.7% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is presently 30.95%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Friday, March 27th. TD Cowen reduced their price objective on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Piper Sandler started coverage on Danaher in a research report on Thursday. They set a “neutral” rating and a $200.00 price objective for the company. Evercore upped their target price on Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a report on Tuesday, April 21st. Finally, Wells Fargo & Company dropped their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $233.61.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.